CA3245204A1 - HETEROCYCLIC DERIVATIVES WITH MEDIUM OR MACROCYCLIC BENZYL SUBSTITUTION AND ASSOCIATED USES - Google Patents
HETEROCYCLIC DERIVATIVES WITH MEDIUM OR MACROCYCLIC BENZYL SUBSTITUTION AND ASSOCIATED USESInfo
- Publication number
- CA3245204A1 CA3245204A1 CA3245204A CA3245204A CA3245204A1 CA 3245204 A1 CA3245204 A1 CA 3245204A1 CA 3245204 A CA3245204 A CA 3245204A CA 3245204 A CA3245204 A CA 3245204A CA 3245204 A1 CA3245204 A1 CA 3245204A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- alkyl
- halogen
- pharmaceutically acceptable
- present disclosure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263315438P | 2022-03-01 | 2022-03-01 | |
| US63/315,438 | 2022-03-01 | ||
| US202363439477P | 2023-01-17 | 2023-01-17 | |
| US63/439,477 | 2023-01-17 | ||
| PCT/US2023/014275 WO2023167925A1 (en) | 2022-03-01 | 2023-03-01 | Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and related uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3245204A1 true CA3245204A1 (en) | 2023-09-07 |
Family
ID=85772026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3245204A Pending CA3245204A1 (en) | 2022-03-01 | 2023-03-01 | HETEROCYCLIC DERIVATIVES WITH MEDIUM OR MACROCYCLIC BENZYL SUBSTITUTION AND ASSOCIATED USES |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20250236629A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4486748A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025507852A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240157067A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119110802A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023228830A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3245204A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2024002576A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL315237A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024010608A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202400606A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023167925A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12503475B2 (en) | 2020-09-03 | 2025-12-23 | Centessa Pharmaceuticals (Uk) Limited | Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists |
| WO2022207935A1 (en) | 2021-04-02 | 2022-10-06 | Orexia Therapeutics Limited | 2-(3-ethynylbenzyl)-substituted heterocycle derivatives as orexin-2 agonists |
| EP4680611A1 (en) | 2023-03-16 | 2026-01-21 | Takeda Pharmaceutical Company Limited | Macrocyclic heterocycle compounds and use thereof |
| JP2026518313A (ja) | 2023-06-01 | 2026-06-04 | ハー・ルンドベック・アクチエゼルスカベット | スピロ大環状オレキシン2受容体アゴニスト |
| CN122374291A (zh) | 2023-12-12 | 2026-07-10 | 爱杜西亚药品有限公司 | 作为食欲素受体调节剂的芳基砜及砜酮衍生物 |
| WO2025132542A1 (en) | 2023-12-19 | 2025-06-26 | Idorsia Pharmaceuticals Ltd | Macrocyclic orexin agonists |
| US20260144795A1 (en) | 2024-11-27 | 2026-05-28 | H. Lundbeck A/S | Spiromacrocyclic orexin 2 receptor agonists |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
| US10428023B2 (en) | 2017-08-03 | 2019-10-01 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| PE20211700A1 (es) | 2019-01-31 | 2021-09-01 | Takeda Pharmaceuticals Co | Compuesto heterociclico y su uso |
| KR20260083444A (ko) * | 2019-11-25 | 2026-06-05 | 알케르메스,인코포레이티드 | 치환된 마크로사이클릭 화합물 및 관련 치료 방법 |
| CN116635393A (zh) * | 2020-09-03 | 2023-08-22 | 欧瑞夏治疗有限公司 | 中环或大环苄基取代的杂环衍生物及其作为食欲素-2受体激动剂的用途 |
-
2023
- 2023-03-01 WO PCT/US2023/014275 patent/WO2023167925A1/en not_active Ceased
- 2023-03-01 KR KR1020247032615A patent/KR20240157067A/ko active Pending
- 2023-03-01 EP EP23713207.1A patent/EP4486748A1/en active Pending
- 2023-03-01 IL IL315237A patent/IL315237A/en unknown
- 2023-03-01 TW TW112107384A patent/TW202400606A/zh unknown
- 2023-03-01 JP JP2024551975A patent/JP2025507852A/ja active Pending
- 2023-03-01 MX MX2024010608A patent/MX2024010608A/es unknown
- 2023-03-01 CA CA3245204A patent/CA3245204A1/en active Pending
- 2023-03-01 CN CN202380037293.8A patent/CN119110802A/zh active Pending
- 2023-03-01 AU AU2023228830A patent/AU2023228830A1/en active Pending
-
2024
- 2024-08-28 US US18/817,943 patent/US20250236629A1/en active Pending
- 2024-08-29 CL CL2024002576A patent/CL2024002576A1/es unknown
-
2025
- 2025-04-11 US US19/177,396 patent/US20250289828A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240157067A (ko) | 2024-10-31 |
| TW202400606A (zh) | 2024-01-01 |
| US20250289828A1 (en) | 2025-09-18 |
| JP2025507852A (ja) | 2025-03-21 |
| MX2024010608A (es) | 2024-09-23 |
| CL2024002576A1 (es) | 2025-01-10 |
| EP4486748A1 (en) | 2025-01-08 |
| AU2023228830A1 (en) | 2024-09-12 |
| CN119110802A (zh) | 2024-12-10 |
| US20250236629A1 (en) | 2025-07-24 |
| WO2023167925A1 (en) | 2023-09-07 |
| IL315237A (en) | 2024-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12503475B2 (en) | Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists | |
| EP4208465A1 (en) | Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and their uses as orexin-2 receptor agonists | |
| AU2023228830A1 (en) | Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and related uses | |
| CA2975605C (en) | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors | |
| AU2024350399A1 (en) | Ras-pi3k inhibitors for the treatment of cancer and immunological diseases | |
| IL275058B2 (en) | Sulfonylurea derivatives as modulators of the NLRP3 inflammasome | |
| EP4486445A1 (en) | Bicyclic-heterocycle derivatives and related uses | |
| WO2022207935A1 (en) | 2-(3-ethynylbenzyl)-substituted heterocycle derivatives as orexin-2 agonists | |
| TW201734001A (zh) | ROR-γ調節劑 | |
| WO2021170627A1 (en) | Difluorocyclohexyl derivatives as il-17 modulators | |
| TW202233620A (zh) | Cftr調節劑化合物、組合物及其用途 | |
| US20240083872A1 (en) | Cyclic amine derivatives having serotonin receptor binding activity | |
| JP2024532729A (ja) | フェロトーシス調節物質、その調製及び使用 | |
| AU2019223882B2 (en) | Receptor inhibitors, pharmaceutical compositions comprising the same, and usage thereof | |
| CA3180417A1 (en) | Synthesis of (2s,5r)-5-(2-chlorophenyl)-1-(2'-methoxy-[1,1'-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid | |
| EA052303B1 (ru) | Средне- или макроциклические производные бензилзамещенного гетероцикла и связанные с ними применения | |
| TW202530205A (zh) | 經取代之芳基磺醯胺及其組合物及用途 | |
| TW202537962A (zh) | 抑制α-V β-1整合素 | |
| WO2025211975A1 (en) | Orexin receptor agonists | |
| KR20260012686A (ko) | 신규한 오렉신 2 수용체 작용제 및 이의 용도 | |
| JP2026515668A (ja) | 新規な化合物及びその使用 | |
| HK1228903A1 (en) | 5,6-disubstituted pyridine-2-carboxamides as cannabinoid receptor agonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240828 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20240829 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20240829 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20240829 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250212 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250321 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250321 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250321 |